Healthy volunteers help test new drug for brain inflammation
NCT ID NCT06753955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single dose of a new drug called ART5803 in 7 healthy adults to see if it is safe and how it interacts with another medicine (IVIG). The goal was to gather information for future research on autoimmune encephalitis, a condition where the immune system attacks the brain. Participants did not have the disease and received no direct treatment benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Can we predict who will relapse after brain inflammation?
- New study tracks pregnancy in women with neuroimmune diseases
- New study uses advanced scans to map brain inflammation over time
- Could Immune-Boosting drugs treat certain psychosis?
- New antibody drug aims to block Brain-Attacking autoantibodies